Esophageal squamous cell carcinoma (ESCC) is a lethal malignancy. However, there are few useful markers for diagnosis and treatment. Glutathione S‐transferase Pi 1 (GSTP1) has been reported as a predictor of malignancy or anticancer drug resistance in some cancers. We investigated the association of GSTP1 expression with the malignancy or drug resistance in ESCC cell lines and clinical tissue samples. Proliferation and apoptosis assays regarding GSTP1 expression were examined in ESCC cell lines. Proliferation of GSTP1 knockdown cells was significantly decreased (P < .01), and the frequency of early apoptosis was increased (P < .05). Invasion capacity of GSTP1 knockdown cells was slightly decreased in transwell assay. These results suggest that GSTP1 plays an important role in malignant potential. To examine the effects of GSTP1 on drug resistance, chemosensitivity assay and apoptosis assay under cisplatin exposure were carried out. Viability of GSTP1 knockdown cells treated with cisplatin was lower than that of control cells (P < .01). Moreover, the frequency of early and late apoptosis in GSTP1 knockdown cells was markedly increased over that of control cells by cisplatin exposure (P < .01). In immunohistochemistry assay of resected tissue samples, GSTP1 expression was significantly associated with clinical downstaging (P = .04) in 72 ESCC patients with neoadjuvant chemotherapy. Furthermore, there was a significant association between GSTP1 expression in resected tissue and biopsy samples in 34 ESCC patients without neoadjuvant chemotherapy (P = .02). In summary, GSTP1 was related to malignant potential and may be a predictive marker of drug resistance in ESCC patients.
Background Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies worldwide, however, there is no useful marker for diagnosis and treatment. Glutathione S-transferase Pi 1 (GSTP1) is a member of GST family, a phase-II metabolic enzyme, and has reported as a predictor of malignancy and sensitivity to anti-cancer drugs in some cancers. In this study, we investigated the association of GSTP1 expression with malignancy and resistance to chemotherapy in ESCC patients. Methods The ability of proliferation and sensitivity to anti-cancer drugs regarding GSTP1 expression were examined in ESCC cell lines, KYSE170 and TE13. Proliferation assay and apoptosis assay using fluorescent activated cell sorting (FACS) were performed. In addition, immunohistochemistry assays of tissue samples were performed in 75 ESCC patients without neoadjuvant chemotherapy and 71 patients with neoadjuvant chemotherapy. Results The proliferation of GSTP1 knockdown cells were significantly decreased compared to that of control cells in KYSE170 and TE13. Similarly, the frequency of early apoptosis in GSTP1 knockdown cells were higher than that of control cells. Survival rate of GSTP1 knockdown cells treated with cisplatin was lower than that of control cells in chemoresistance assays. Moreover, the frequency of early apoptosis in GSTP1 knockdown cells treated with cisplatin were markedly higher than that of control cells. In immunohistochemistry assay of ESCC patients without neoadjuvant chemotherapy, high GSTP1 expression was an independent predictor of a poor prognosis (P = 0.029). Regarding immunohistochemistry assay of tissue samples with neoadjuvant chemotherapy, GSTP1 expression significantly associated with downstaging of clinical stage (P = 0.042). Conclusion GSTP1 related to the prognosis and resistance to chemotherapy in ESCC patients. However, accurate assessment of resected specimen with chemotherapy was difficult because tumor cells sensitive to chemotherapy were already absent. Further analysis using samples without chemotherapy such as biopsy samples would be more appropriate for the assessment of the sensitivity to chemotherapy. Disclosure All authors have declared no conflicts of interest.